AngioDynamics – Earnings worse than estimates
AngioDynamics, Inc. (NASDAQ:ANGO). Last Market Price: 13.63, Change: -0.64, % Change: (-4.48%). Shares trade in the range of 13.53 – 14.66 dollars. It has a market capitalization of 340.58M dollars, making it a Small Cap Stock and has 24.99M outstanding shares. The company has a beta of 0.68, indicating, the stock to be less volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is 0.3; P/E of 45.12. It operates in Healthcare sector and belongs to Medical Equipment and Supplies industry. Percentage shares held by institutional investors is 97%. The company has a 52 week high of $ 17.73 and a 52 week low of $ 12.60. Average volumes of shares traded daily are 134,619. Volume traded in the last session was at 72,236, 0.54 times the average volume.
- Reports Q1 (Aug)
- EPS $0.08 worse than the market estimates
- Revenues rose 5.6% year on year to $54.4 million
For Q2 (May ’11), It had a Net profit margin of -1.53%, an Operating margin of -3.85%. Other Key stats and ratios are : Return on average assets of -0.79%, Return on average equity of -0.85%. The organization has an employee strength of 722
Consensus Recommendation is a Outperform.
Estimate for sales for the Quarter Ending Nov-11 show a mean of 55.74 million dollars, an estimate high of 56.20 million dollars and an estimate low of 55.00 million dollars. A year ago the figures stood at 57.90 million dollars.
Estimate for sales for the Quarter Ending Feb-12 show a mean of 54.76 million dollars, an estimate high of 56.80 million dollars and an estimate low of 52.50 million dollars. A year ago the figures stood at 58.60 million dollars.
Estimate for EPS for the Quarter Ending Nov-11 show a mean of 0.13 dollars, an estimate high of 0.18 dollars and an estimate low of 0.10 dollars. A year ago the figures stood at 0.14 dollars.
Estimate for EPS for the Quarter Ending Feb-12 show a mean of 0.12 dollars, an estimate high of 0.18 dollars and an estimate low of 0.09 dollars. A year ago the figures stood at 0.15 dollars.
Sales for Quarter Ending May-11 was estimated at 56.87 million dollars, however the actual sales figure stood at 56.43 million dollars, 0.44 million dollars less than estimates.
Sales for Quarter Ending Feb-11 was estimated at 53.89 million dollars, however the actual sales figure stood at 54.65 million dollars, 0.76 million dollars more than estimates.
Post Written By: Ed Liston
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht. |